 NEW YORK and LONDON, May 25, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc NASDAQ: TLSA, LSE: TILS Tiziana or the Company, a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the first patient with secondary progressive multiple sclerosis SPMS was dosed with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Womens Hospital BWH, Harvard Medical School, Boston, MA. Nasal Foralumab 50 mcg 25 mcgnostril will be administered in 3-week cycles, with 3 timesweek dosing for the first 2 weeks followed by 1 week of rest period. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. The study will also examine microglial activation, by positron emission tomography PET, immunological and neurodegenerative markers to assess clinical responses following the treatment regimen. 